查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493513

聚乙二醇化蛋白质市场 - 全球产业规模、份额、趋势、机会和预测，按产品（消费品、服务）、蛋白质类型、应用、最终用途、地区和竞争细分，2019-2029F

PEGylated Proteins Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Consumable, Services), By Protein Type, By Application, By End-Use, By Region, and By Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023 年全球聚乙二醇化蛋白质市场价值为9.4971 亿美元，预计到2029 年预测期内将以9.82% 的复合年增长率稳步增长。连接到蛋白质分子上的生物共轭物。这个过程称为聚乙二醇化，可改变蛋白质的理化性质，进而增强药物动力学、降低免疫原性并提高治疗效果。聚乙二醇化涉及将聚乙二醇聚合物链附着到蛋白质分子表面上的特定胺基酸残基。这可以透过各种化学缀合方法来实现，包括胺反应化学、硫醇反应化学和生物正交反应，取决于蛋白质和 PEG 分子上存在的官能基。聚乙二醇化增加了蛋白质的流体动力学大小和分子量，导致肾臟滤过减少和蛋白质分解降解。

市场概况
预测期 2025-2029
2023 年市场规模 94971万美元
2029 年市场规模 16.5968亿美元
2024-2029 年复合年增长率 9.82%
成长最快的细分市场 服务
最大的市场 北美洲

与非聚乙二醇化蛋白相比，聚乙二醇化蛋白在血流中的循环时间较长，清除率较低，半衰期较长。这可以减少给药间隔和持续的药物暴露，从而提高治疗效果和患者的依从性。聚乙二醇化透过保护蛋白质免受生理环境中的酵素降解、化学变性和聚集来赋予蛋白质稳定性。亲水性 PEG 链在蛋白质核心周围形成水合层，稳定其天然构形并在配製、储存和给药过程中保留其生物活性。这种增强的稳定性提高了聚乙二醇化蛋白质疗法的保质期和可靠性。

聚乙二醇化透过延长蛋白质的循环半衰期、降低免疫原性和增强生理环境中的稳定性来改善蛋白质的药物动力学特性。与非聚乙二醇化蛋白质相比，聚乙二醇化蛋白质表现出更长的功效并降低了给药频率，提供了显着的临床益处并提高了患者的依从性。聚乙二醇化蛋白质被用作药物递送系统的载体，使治疗剂能够靶向和受控地释放到特定组织或细胞。

聚乙二醇化可增强药物的溶解度、生物利用度和组织渗透性，促进药物递送至疾病部位，同时最大限度地减少脱靶效应和全身毒性。蛋白质工程、缀合化学和药物製剂技术的不断进步加速了新型聚乙二醇化蛋白质的开发，其具有改善的治疗特性和增强的功能。聚乙二醇化技术和连接化学的创新能够精确控制药物释放动力学和位点特异性靶向，从而扩大了聚乙二醇化蛋白在多种疾病适应症中的治疗潜力。

主要市场驱动因素

技术进步

增强的药物动力学特性

扩大药物传递领域的应用

主要市场挑战

免疫原性问题

来自生物相似药和仿製药的竞争

主要市场趋势

增加治疗应用

细分市场洞察

产品洞察

蛋白质类型见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球聚乙二醇化蛋白市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品（消费品、服务）
    • 依蛋白质类型（集落刺激因子、干扰素、促红血球生成素、单株抗体、重组因子 VII 等）
    • 依应用分类（癌症治疗、肝炎、慢性肾臟病、血友病、多发性硬化症、胃肠道疾病等）
    • 依最终用途（製药、生技公司、CRO 和学术研究机构等）
    • 按地区
    • 按公司划分 (2023)
  • 市场地图

第 6 章：北美聚乙二醇化蛋白市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依蛋白质类型
    • 按申请
    • 按最终用途
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲聚乙二醇化蛋白市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依蛋白质类型
    • 按申请
    • 按最终用途
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区聚乙二醇化蛋白市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依蛋白质类型
    • 按申请
    • 按最终用途
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲聚乙二醇化蛋白市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依蛋白质类型
    • 按申请
    • 按最终用途
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲聚乙二醇化蛋白市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依蛋白质类型
    • 按申请
    • 按最终用途
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 併购（如有）
  • 产品发布（如有）
  • 最近的发展

第 13 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Celares GmbH
  • Quanta BioDesign, Ltd
  • Biomatrik Inc
  • Laysan Bio Inc.
  • Iris Biotech GMBH
  • Valley Proteins, Inc.
  • Enzon Pharamaceuticals, Inc
  • Takeda Pharmaceuticals Company Limited

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 24049

Global PEGylated Proteins Market was valued at USD 949.71 million in 2023 and is expected to experience a steady growth in the forecast period at a CAGR of 9.82% through 2029. PEGylated proteins are bioconjugates where polyethylene glycol (PEG) chains are covalently attached to protein molecules. This process, known as PEGylation, modifies the physicochemical properties of proteins, leading to enhanced pharmacokinetics, reduced immunogenicity, and improved therapeutic efficacy. PEGylation involves the attachment of PEG polymer chains to specific amino acid residues on the surface of protein molecules. This can be achieved through various chemical conjugation methods, including amine-reactive chemistry, thiol-reactive chemistry, and bio orthogonal reactions, depending on the functional groups present on both the protein and the PEG molecule. PEGylation increases the hydrodynamic size and molecular weight of proteins, leading to decreased renal filtration and proteolytic degradation.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 949.71 Million
Market Size 2029USD 1,659.68 Million
CAGR 2024-20299.82%
Fastest Growing SegmentServices
Largest MarketNorth America

PEGylated proteins exhibit prolonged circulation times in the bloodstream, with reduced clearance rates and extended half-lives compared to their non-PEGylated counterparts. This allows for less frequent dosing intervals and sustained drug exposure, improving therapeutic efficacy and patient compliance. PEGylation confers stability to proteins by protecting them from enzymatic degradation, chemical denaturation, and aggregation in physiological environments. The hydrophilic PEG chains create a hydrated layer around the protein core, stabilizing its native conformation and preserving its biological activity during formulation, storage, and administration. This enhanced stability enhances the shelf life and reliability of PEGylated protein therapeutics.

PEGylation improves the pharmacokinetic properties of proteins by extending their circulating half-life, reducing immunogenicity, and enhancing stability in physiological environments. PEGylated proteins exhibit prolonged efficacy and reduced dosing frequency compared to their non-PEGylated counterparts, offering significant clinical benefits and improved patient compliance. PEGylated proteins are utilized as carriers for drug delivery systems, enabling targeted and controlled release of therapeutic agents to specific tissues or cells.

PEGylation enhances the solubility, bioavailability, and tissue penetration of drugs, facilitating their delivery to disease sites while minimizing off-target effects and systemic toxicity. Ongoing advancements in protein engineering, conjugation chemistry, and drug formulation technologies have accelerated the development of novel PEGylated proteins with improved therapeutic properties and enhanced functionality. Innovations in PEGylation techniques and linker chemistries enable precise control over drug release kinetics and site-specific targeting, expanding the therapeutic potential of PEGylated proteins across diverse disease indications.

Key Market Drivers

Technological Advancements

Protein engineering techniques enable the design and modification of PEGylated proteins to enhance their stability under various physiological conditions. By introducing specific amino acid substitutions or structural modifications, engineers can mitigate protein degradation and improve product shelf life, thereby increasing the attractiveness of PEGylated proteins for therapeutic applications. Protein engineering allows for the precise tuning of pharmacokinetic properties such as circulating half-life and biodistribution of PEGylated proteins. Through rational design and molecular modeling approaches, researchers can tailor the size, charge, and hydrophilicity of PEG moieties to optimize drug pharmacokinetics, resulting in prolonged circulation times and improved therapeutic efficacy.

One of the challenges associated with protein therapeutics, including PEGylated proteins, is immunogenicity, which can lead to adverse immune reactions and treatment discontinuation. Protein engineering strategies enable the identification and elimination of immunogenic epitopes while preserving protein functionality, thereby reducing the risk of immune responses, and enhancing patient safety. Traditional PEGylation methods often result in heterogeneous product mixtures with variable drug conjugation sites and functional activity. Advances in protein engineering facilitate site-specific PEGylation, enabling precise attachment of PEG moieties to predetermined locations on the protein surface. Site-specific PEGylation enhances product consistency, purity, and therapeutic performance, driving adoption in the biopharmaceutical industry.

Protein engineering enables the design of multi-functional PEGylated proteins with diverse biological activities and therapeutic modalities. By incorporating targeting ligands, enzymatic payloads, or fusion domains into PEGylated protein scaffolds, engineers can create multifunctional biologics capable of targeting specific tissues, modulating immune responses, or exerting synergistic therapeutic effects, expanding the scope of applications in drug delivery and disease treatment. Advances in high-throughput screening techniques and directed evolution methodologies accelerate the discovery and optimization of PEGylated proteins with desired pharmacological properties.

Through iterative cycles of mutagenesis, selection, and screening, researchers can engineer PEGylated proteins with enhanced affinity, specificity, and stability, facilitating the development of next-generation biologics with improved clinical performance. Combinatorial approaches and synthetic biology techniques enable the rapid generation of diverse PEGylated protein libraries for screening and optimization. By harnessing the power of synthetic biology tools such as gene synthesis, DNA shuffling, and protein display technologies, scientists can explore vast sequence space and identify novel PEGylated protein variants with tailored functionalities and therapeutic profiles, driving innovation in drug discovery and development. This factor will help in the development of the Global PEGylated Proteins Market.

Enhanced Pharmacokinetic Properties

PEGylation, the process of attaching polyethylene glycol (PEG) chains to proteins, imparts steric hindrance and increases the hydrodynamic volume of proteins. This modification reduces renal clearance and proteolytic degradation of proteins, resulting in prolonged circulation times in the bloodstream. PEGylated proteins exhibit slower clearance rates compared to their non-PEGylated counterparts, leading to extended therapeutic effects and reduced dosing frequency. PEGylation enhances the bioavailability of proteins by protecting them from enzymatic degradation and immune recognition in the bloodstream. The covalent attachment of PEG chains shields protein antigens from proteases and immunoglobulins, thereby reducing their clearance and degradation rates. This increased stability and bioavailability result in higher systemic exposure to therapeutic proteins, maximizing their pharmacological effects and therapeutic outcomes.

PEGylated proteins possess improved tissue penetration and distribution characteristics compared to unmodified proteins. The hydrated PEG chains create a hydrophilic "brush" layer around the protein surface, preventing non-specific interactions with plasma proteins and cell membranes. This stealth effect enables PEGylated proteins to penetrate deep into target tissues and reach intracellular compartments more efficiently, enhancing their therapeutic efficacy in treating localized and systemic diseases.

PEGylation reduces the immunogenicity of therapeutic proteins by masking antigenic epitopes and minimizing immune recognition and clearance. The PEG chains act as "stealth" coatings that camouflage the protein surface from immune surveillance, thereby reducing the risk of immune responses and neutralizing antibodies. This decreased immunogenicity enhances the safety and tolerability of PEGylated proteins, allowing for repeated administration and prolonged treatment regimens without eliciting adverse immune reactions. PEGylation enables the customization of pharmacokinetic profiles to meet specific therapeutic requirements and patient needs.

By varying the size, structure, and density of PEG chains, researchers can modulate the rate of renal excretion, tissue distribution, and metabolic clearance of PEGylated proteins. This tunable pharmacokinetics allows for precise control over drug exposure levels and duration of action, optimizing therapeutic efficacy while minimizing off-target effects and toxicity. The extended half-life and reduced dosing frequency of PEGylated proteins enhance patient convenience and compliance with treatment regimens. Patients receiving PEGylated protein therapies require fewer injections or infusions, resulting in reduced treatment burden, improved adherence, and better overall clinical outcomes. This dosing convenience contributes to patient satisfaction and acceptance of PEGylated protein therapies as preferred treatment options for chronic and debilitating diseases. This factor will pace up the demand of the Global PEGylated Proteins Market.

Expanding Applications in Drug Delivery

PEGylation enhances the pharmacokinetic properties of proteins by increasing their circulating half-life and reducing renal clearance. This extended circulation time allows for sustained drug release and prolonged therapeutic effects, making PEGylated proteins well-suited for drug delivery applications requiring controlled release and systemic exposure. PEGylation confers stability to proteins, protecting them from enzymatic degradation and denaturation in biological fluids and harsh physiological environments. PEGylated proteins exhibit improved stability during storage, transportation, and administration, enabling formulation as long-acting injectables, depot formulations, or sustained-release formulations for controlled drug delivery. PEGylated proteins can be engineered to target specific tissues, cells, or receptors through ligand-receptor interactions or receptor-mediated endocytosis.

By conjugating targeting ligands or antibodies to PEGylated proteins, drug delivery systems can achieve site-specific accumulation and enhanced therapeutic efficacy while minimizing off-target effects and systemic toxicity. PEGylation enhances the tissue penetration and distribution of proteins by reducing non-specific interactions with plasma proteins and extracellular matrix components. PEGylated proteins can penetrate deep into tumor tissues, inflamed tissues, or physiological barriers such as the blood-brain barrier, facilitating drug delivery to target sites and overcoming biological barriers that limit therapeutic access.

PEGylation reduces the immunogenicity and antigenicity of proteins, minimizing immune responses and adverse reactions upon administration. This enhanced biocompatibility and reduced toxicity profile make PEGylated proteins ideal candidates for drug delivery systems, enabling safe and well-tolerated administration routes such as parenteral injection, oral delivery, nasal delivery, or pulmonary delivery. PEGylated proteins offer versatile formulation options for drug delivery applications, including nanoparticles, micelles, liposomes, hydrogels, and polymer conjugates. These formulation platforms can encapsulate, stabilize, and deliver therapeutic payloads while providing tunable release kinetics, sustained drug release profiles, and improved bioavailability for a wide range of small molecules, peptides, and biologics.

PEGylation enables the customization of drug delivery systems to meet specific therapeutic requirements and patient needs. By modulating the size, shape, surface charge, and PEGylation density of delivery vehicles, researchers can tailor drug pharmacokinetics, biodistribution, and release kinetics to optimize therapeutic outcomes and minimize side effects in targeted patient populations. This factor will accelerate the demand of the Global PEGylated Proteins Market.

Key Market Challenges

Immunogenicity Concerns

PEGylation involves conjugating PEG chains to proteins. While PEGylation can shield proteins from immune recognition, the protein component of PEGylated proteins may still elicit immune responses, especially if it's foreign or derived from non-human sources. These immune responses can range from mild allergic reactions to more severe immune-mediated adverse events. Immune responses against PEGylated proteins can lead to their accelerated clearance from the bloodstream or neutralization of their therapeutic activity. This can result in reduced efficacy and treatment failure, particularly in patients requiring long-term or repeated administration of PEGylated protein therapies.

Immunogenicity can have significant clinical implications for patient safety and treatment outcomes. Immune reactions to PEGylated proteins may manifest as infusion reactions, hypersensitivity responses, or autoimmune phenomena, necessitating close monitoring, dose adjustments, or discontinuation of therapy in affected individuals. Although PEG is considered biocompatible and has been used extensively in pharmaceuticals, some individuals may develop antibodies against PEG. This can lead to hypersensitivity reactions and reduced efficacy of PEGylated proteins over time. The prevalence and clinical significance of anti-PEG antibodies are still being studied, but they represent a potential safety concern.

Competition from Biosimilars and Generics

As patents for original PEGylated protein drugs expire, they become vulnerable to competition from biosimilar and generic manufacturers. Once market exclusivity ends, biosimilar and generic versions of PEGylated proteins can enter the market, offering similar therapeutic effects at potentially lower prices. The introduction of biosimilars and generics often leads to price erosion and cost pressures in the PEGylated proteins market. Increased competition among manufacturers drives down prices, resulting in reduced profit margins for originator companies and price-based competition among biosimilar and generic products. The availability of multiple biosimilar and generic versions of PEGylated proteins can lead to market saturation and fragmentation. With numerous competing products available, healthcare providers and payers face challenges in selecting and managing treatment options, leading to increased complexity and administrative burden in healthcare decision-making.

Biosimilar and generic versions of PEGylated proteins must demonstrate similarity in terms of safety, efficacy, and quality compared to the reference product. Concerns regarding the analytical similarity, immunogenicity, and manufacturing processes of biosimilars and generics may arise, potentially impacting physician and patient confidence in their therapeutic equivalence and interchangeability. Established brand loyalty and physician preference for originator PEGylated protein drugs may pose barriers to the adoption of biosimilars and generics. Physicians may hesitate to switch patients from familiar branded products to biosimilar or generic alternatives, citing concerns about efficacy, safety, and clinical outcomes.

Key Market Trends

Increasing Therapeutic Applications

PEGylated proteins are extensively used in oncology for the treatment of various cancers. PEGylated versions of therapeutic proteins such as interferons, cytokines, and monoclonal antibodies are engineered to target tumor cells, inhibit tumor growth, and modulate the immune response against cancer. PEGylation improves the stability and half-life of anticancer agents, allowing for sustained drug exposure and enhanced therapeutic efficacy while minimizing systemic toxicity. PEGylated proteins are employed in the treatment of hematological disorders such as anemia, thrombocytopenia, and hemophilia. Erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) are examples of PEGylated proteins used to stimulate red blood cell and white blood cell production, respectively, in patients with anemia and neutropenia associated with cancer chemotherapy or chronic diseases.

PEGylated proteins play a vital role in the management of autoimmune disorders, including rheumatoid arthritis, multiple sclerosis, and psoriasis. PEGylated tumor necrosis factor (TNF) inhibitors and interleukin receptor antagonists are used to suppress inflammatory responses, alleviate disease symptoms, and prevent joint damage in patients with autoimmune arthritis and inflammatory bowel disease. PEGylated proteins are utilized in the treatment of metabolic disorders such as diabetes, hypercholesterolemia, and obesity. PEGylated insulin analogs and glucagon-like peptide-1 (GLP-1) receptor agonists offer improved glycemic control and weight management in patients with type 1 and type 2 diabetes mellitus, while PEGylated lipoprotein lipase (LPL) activators reduce triglyceride levels and improve lipid metabolism in patients with hypertriglyceridemia.

Segmental Insights

Product Insights

The Consumable segment is projected to experience significant dominance in the Global PEGylated Proteins Market during the forecast period. PEGylation continues to gain traction in the biopharmaceutical industry for improving the pharmacokinetic properties and therapeutic efficacy of proteins, there is a growing demand for consumables used in PEGylation processes. These consumables include PEGylation reagents, linker molecules, activated PEG derivatives, and other biochemicals necessary for protein modification and conjugation. The growing popularity of biologic therapeutics, including PEGylated proteins, drives the demand for consumables used in their manufacturing processes. Biopharmaceutical companies and contract manufacturing organizations (CMOs) require high-quality consumables and reagents to support the production of PEGylated proteins at scale, ensuring consistency, purity, and product quality throughout the manufacturing process.

The expansion of bioprocessing facilities and manufacturing capacity to meet the growing demand for biologic therapeutics contributes to increased consumption of consumables in the PEGylated proteins market. Biopharmaceutical companies invest in state-of-the-art facilities equipped with advanced bioprocessing equipment and consumables to support large-scale production of PEGylated proteins for clinical and commercial applications. Consumable suppliers and manufacturers offer customized solutions and services tailored to the specific requirements of PEGylation and protein modification applications. This includes the development of specialty reagents, kits, and consumables designed to streamline PEGylation workflows, optimize reaction conditions, and maximize yields, thereby driving efficiency and productivity in protein engineering and bioprocessing operations.

Protein Type Insights

The Colony Stimulating Factors segment is projected to experience significant growth in the Global PEGylated Proteins Market during the forecast period. Colony stimulating factors play a crucial role in stimulating the production of white blood cells, particularly neutrophils, which are often depleted during chemotherapy treatment. Chemotherapy-induced neutropenia increases the risk of infections and can lead to treatment delays or dose reductions. PEGylated CSFs offer a longer circulating half-life compared to conventional CSFs, providing sustained neutrophil support, and reducing the frequency of injections needed for patients undergoing chemotherapy. PEGylation enhances the pharmacokinetic profile of CSFs by increasing their stability and extending their circulating half-life in the bloodstream. PEGylated CSFs exhibit reduced renal clearance and proteolytic degradation, resulting in more predictable and sustained levels of neutrophil support over an extended duration.

This improved pharmacokinetic profile enhances patient convenience and compliance with treatment regimens. PEGylation can reduce the immunogenicity of CSFs by masking immunogenic epitopes and reducing antibody recognition and neutralization. This helps mitigate the risk of immune reactions and hypersensitivity responses associated with the administration of CSFs, ensuring safer and more tolerable treatment options for patients receiving chemotherapy. PEGylated CSFs offer the advantage of less frequent dosing schedules compared to conventional CSFs, reducing the burden of treatment administration, and improving patient compliance. Patients undergoing chemotherapy can benefit from fewer injections and clinic visits while receiving consistent and sustained neutrophil support throughout their treatment cycles.

Regional Insights

North America emerged as the dominant player in the Global PEGylated Proteins Market in 2023. North America, particularly the United States, is home to a robust biopharmaceutical industry with a significant focus on research and development of protein-based therapeutics. The region boasts numerous biotechnology and pharmaceutical companies that specialize in developing and commercializing biologics, including PEGylated proteins. The region's advanced healthcare infrastructure, including well-established academic and research institutions, supports innovation and collaboration in biopharmaceutical research. North America benefits from a wealth of scientific expertise and resources dedicated to advancing drug discovery and development processes.

The regulatory framework governing drug approval and commercialization in North America, particularly the United States, is well-defined and transparent. The U.S. Food and Drug Administration (FDA) provides clear guidelines and pathways for the development and regulatory approval of biologic drugs, including PEGylated proteins, which facilitates market entry for manufacturers. North America offers access to abundant capital and funding sources for biopharmaceutical research and development. Venture capital firms, private equity investors, and government funding agencies actively support biotech startups and established companies pursuing innovative therapies, including PEGylated proteins.

Key Market Players

Thermo Fisher Scientific Inc.

Merck KGaA

Celares GmbH

Quanta BioDesign, Ltd

Biomatrik Inc

Laysan Bio Inc.

Iris Biotech GMBH

Valley Proteins, Inc.

Enzon Pharamaceuticals, Inc

Takeda Pharmaceuticals Company Limited

Report Scope:

In this report, the Global PEGylated Proteins Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

PEGylated Proteins Market, By Product:

    Consumable

PEGylation Kits Reagents

Monofunctional Linear PEGs

Bifunctional PEGs

others

PEGylation Kits

    Services

PEGylated Proteins Market, By Protein Type:

    Colony Stimulating Factors Interferons Erythropoietin mAbs Recombinant Factor VII Others

PEGylated Proteins Market, By Application:

    Cancer Treatment Hepatitis Chronic Kidney Diseases Hemophilia Multiple Sclerosis Gastrointestinal Disorders Others

PEGylated Proteins Market, By End-Use:

    Pharmaceuticals Biotechnology Companies CROs and Academic Research Institutes Others

PEGylated Proteins Market, By Region:

    North America

United States

Canada

Mexico

    Europe

Germany

United Kingdom

France

Italy

Spain

    Asia-Pacific

China

Japan

India

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global PEGylated Proteins Market.

Available Customizations:

Global PEGylated Proteins market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global PEGylated Proteins Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Consumable, Services)
      • 5.2.1.1. By Consumable (PEGylation Kits Reagents, PEGylation Kits)
        • 5.2.1.1.1. By PEGylation Kits Reagents (Monofunctional Linear PEGs, Bifunctional PEGs, others)
    • 5.2.2. By Protein Type (Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VII and Others)
    • 5.2.3. By Application (Cancer Treatment, Hepatitis, Chronic Kidney Diseases, Hemophilia, Multiple Sclerosis, Gastrointestinal Disorders and Others)
    • 5.2.4. By End-Use (Pharmaceuticals, Biotechnology Companies, CROs and Academic Research Institutes, others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2023)
  • 5.3. Market Map

6. North America PEGylated Proteins Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Protein Type
    • 6.2.3. By Application
    • 6.2.4. By End-Use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States PEGylated Proteins Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Protein Type
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End-Use
    • 6.3.2. Canada PEGylated Proteins Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Protein Type
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End-Use
    • 6.3.3. Mexico PEGylated Proteins Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Protein Type
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End-Use

7. Europe PEGylated Proteins Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Protein Type
    • 7.2.3. By Application
    • 7.2.4. By End-Use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany PEGylated Proteins Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Protein Type
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End-Use
    • 7.3.2. United Kingdom PEGylated Proteins Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Protein Type
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End-Use
    • 7.3.3. Italy PEGylated Proteins Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Protein Type
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End-Use
    • 7.3.4. France PEGylated Proteins Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Protein Type
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End-Use
    • 7.3.5. Spain PEGylated Proteins Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Protein Type
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End-Use

8. Asia-Pacific PEGylated Proteins Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Protein Type
    • 8.2.3. By Application
    • 8.2.4. By End-Use
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China PEGylated Proteins Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Protein Type
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End-Use
    • 8.3.2. India PEGylated Proteins Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Protein Type
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End-Use
    • 8.3.3. Japan PEGylated Proteins Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Protein Type
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End-Use
    • 8.3.4. South Korea PEGylated Proteins Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Protein Type
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End-Use
    • 8.3.5. Australia PEGylated Proteins Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Protein Type
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End-Use

9. South America PEGylated Proteins Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Protein Type
    • 9.2.3. By Application
    • 9.2.4. By End-Use
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil PEGylated Proteins Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Protein Type
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End-Use
    • 9.3.2. Argentina PEGylated Proteins Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Protein Type
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End-Use
    • 9.3.3. Colombia PEGylated Proteins Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Protein Type
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End-Use

10. Middle East and Africa PEGylated Proteins Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Protein Type
    • 10.2.3. By Application
    • 10.2.4. By End-Use
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa PEGylated Proteins Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Protein Type
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End-Use
    • 10.3.2. Saudi Arabia PEGylated Proteins Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Protein Type
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End-Use
    • 10.3.3. UAE PEGylated Proteins Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Protein Type
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End-Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Thermo Fisher Scientific Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Merck KGaA
  • 14.3. Celares GmbH
  • 14.4. Quanta BioDesign, Ltd
  • 14.5. Biomatrik Inc
  • 14.6. Laysan Bio Inc.
  • 14.7. Iris Biotech GMBH
  • 14.8. Valley Proteins, Inc.
  • 14.9. Enzon Pharamaceuticals, Inc
  • 14.10.Takeda Pharmaceuticals Company Limited

15. Strategic Recommendations

16. About Us & Disclaimer